Two new Miocene limpets (Fissurellidae) from southern California, with notes on other fossil occurrences of the family in northwestern North America

Two new fissurellid limpets (Mollusca: Gastropoda: Fissurellidae), Fissurella? stantoni n. sp. and Scelidotoma aldersoni n. sp., are described from Miocene deposits in southern California. Fissurella? stantoni is described from a single specimen from the middle Miocene Topanga Canyon Formation in the Santa Monica Mountains, Los Angeles County, California. Scelidotoma aldersoni is described from two specimens, one from the middle Miocene Topanga Canyon Formation, and another provisionally (cf.) identified specimen of an internal mold from the middle Miocene “Vaqueros” Formation on Santa Cruz Island, Santa Barbara County, southern California. Other unreported fossil occurrences of Scelidotoma are a juvenile specimen attributed only to genus collected in the middle Eocene Crescent Formation in Washington state and S. bella from the Pliocene part of the San Diego Formation, San Diego County, California. The Scelidotoma occurrences extend the chronostratigraphic range of S. bella from the Holocene (living) to the middle Pliocene, and the range of the genus back to the middle Eocene

A new Lyropecten (Pectinidae, Bivalvia, Mollusca) from the central California Miocene, USA

A new pectinid, Lyropecten terrysmithae n. sp., has been recognized in middle to late Miocene rock units referred to as the Monterey Formation and Santa Margarita Sandstone in the southern Salinas Valley, central California. Previously, L. terrysmithae had been identified as a flat form belonging to either L. estrellanus or L. catalinae, then more recently to Argopecten sp. The earlier assignments were based on its moderate size and a radial rib count nearly identical to these taxa. However, its hinge, flat unledged valves, looped lamellar growth lines, and hinge crura set L. terrysmithae apart from Argopecten and all species of Lyropecten. Localities where it occurs in the Salinas Valley that can be accurately dated are from the late middle to middle late Miocene “Margaritan” California provincial molluscan stage. While L. terrysmithae has been collected at other sites, those localities lack diagnostic age-specific species necessary to determine an accurate geological age and maybe older

Extinction-to-Backscatter Ratios of Saharan Dust Layers Derived from In-Situ Measurements and CALIPSO Overflights During NAMMA

We determine the extinction-to-backscatter (Sa) ratios of dust using (1) airborne in-situ measurements of microphysical properties, (2) modeling studies, and (3) the Cloud-Aerosol Lidar and Infrared Pathfinder Satellite Observations (CALIPSO) observations recorded during the NASA African Monsoon Multidisciplinary Analyses (NAMMA) field experiment conducted from Sal, Cape Verde during Aug-Sept 2006. Using CALIPSO measurements of the attenuated backscatter of lofted Saharan dust layers, we apply the transmittance technique to estimate dust Sa ratios at 532 nm and a 2-color method to determine the corresponding 1064 nm Sa. This method yielded dust Sa ratios of 39.8 plus or minus 1.4 sr and 51.8 plus or minus 3.6 sr at 532 nm and 1064 nm, respectively. Secondly, Sa at both wavelengths is independently calculated using size distributions measured aboard the NASA DC-8 and estimates of Saharan dust complex refractive indices applied in a T-Matrix scheme. We found Sa ratios of 39.1 plus or minus 3.5 sr and 50.0 plus or minus 4 sr at 532 nm and 1064 nm, respectively, using the T-Matrix calculations applied to measured size spectra. Finally, in situ measurements of the total scattering (550 nm) and absorption coefficients (532 nm) are used to generate an extinction profile that is used to constrain the CALIPSO 532 nm extinction profile and thus generate a stratified 532 nm Sa. This method yielded an Sa ratio at 532 nm of 35.7 sr in the dust layer and 25 sr in the marine boundary layer consistent with a predominantly seasalt aerosol near the ocean surface. Combinatorial simulations using noisy size spectra and refractive indices were used to estimate the mean and uncertainty (one standard deviation) of these Sa ratios. These simulations produced a mean (plus or minus uncertainty) of 39.4 (plus or minus 5.9) sr and 56.5 (plus or minus 16.5) sr at 532 nm and 1064 nm, respectively, corresponding to percent uncertainties of 15% and 29%. These results will provide a measurements-based estimate of the dust Sa for use in backscatter lidar inversion algorithms such as CALIOP

CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe

Pooled analysis of WHO Surgical Safety Checklist use and mortality after emergency laparotomy

Background The World Health Organization (WHO) Surgical Safety Checklist has fostered safe practice for 10 years, yet its place in emergency surgery has not been assessed on a global scale. The aim of this study was to evaluate reported checklist use in emergency settings and examine the relationship with perioperative mortality in patients who had emergency laparotomy. Methods In two multinational cohort studies, adults undergoing emergency laparotomy were compared with those having elective gastrointestinal surgery. Relationships between reported checklist use and mortality were determined using multivariable logistic regression and bootstrapped simulation. Results Of 12 296 patients included from 76 countries, 4843 underwent emergency laparotomy. After adjusting for patient and disease factors, checklist use before emergency laparotomy was more common in countries with a high Human Development Index (HDI) (2455 of 2741, 89.6 per cent) compared with that in countries with a middle (753 of 1242, 60.6 per cent; odds ratio (OR) 0.17, 95 per cent c.i. 0.14 to 0.21, P <0001) or low (363 of 860, 422 per cent; OR 008, 007 to 010, P <0.001) HDI. Checklist use was less common in elective surgery than for emergency laparotomy in high-HDI countries (risk difference -94 (95 per cent c.i. -11.9 to -6.9) per cent; P <0001), but the relationship was reversed in low-HDI countries (+121 (+7.0 to +173) per cent; P <0001). In multivariable models, checklist use was associated with a lower 30-day perioperative mortality (OR 0.60, 0.50 to 073; P <0.001). The greatest absolute benefit was seen for emergency surgery in low- and middle-HDI countries. Conclusion Checklist use in emergency laparotomy was associated with a significantly lower perioperative mortality rate. Checklist use in low-HDI countries was half that in high-HDI countries.Peer reviewe

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Measurement of the B+c meson lifetime using B+c→J/ψμ+νμX decays

The lifetime of the $B_c^+$ meson is measured using semileptonic decays having a $J\!/\!\psi$ meson and a muon in the final state. The data, corresponding to an integrated luminosity of $2\mathrm{~fb^{-1}}$, are collected by the LHCb detector in $pp$ collisions at a centre-of-mass energy of $8\,\mathrm{TeV}$. The measured lifetime is $$\tau = 509 \pm 8 \pm 12 \mathrm{~fs},$$ where the first uncertainty is statistical and the second is systematic